Synlogic Inc (SYBX) - News Archive

Synlogic Adopts Limited Duration Stockholders Rights Plan, Engages Ladenburg Thalmann as Financial AdvisorCAMBRIDGE, Mass. - Synlogic, a clinical-stage biotechnology company, has recently announced the adoption of a Lim...

Synlogic Discontinues Synpheny-3 Study and Provides Strategic Corporate Update Synlogic, a leading synthetic biotechnology company, recently made the decision to discontinue its clinical trial for Synpheny-3, following...

Recent innovations in medicine often overturn the conventional understanding of disease management and patient care, and a remarkable case in point is the use of engineered bacteria as therapeutic agents. This fascinati...

As the landscape of innovation and technology within the realm of medicine continuously evolves with unprecedented velocity, it is enthralling to bear witness to the disruptive advancements brought to light by dedicated...

Synthetic biology leader, Synlogic Inc., has recently announced a significant contract with the Air Force Research Laboratory. This recent alignment underscores the company s prowess in process development and manufactu...

CAMBRIDGE, Mass., Oct. 03, 2023 - Synlogic, Inc. (Nasdaq: SYBX), an innovative clinical-stage biotechnology company, has successfully concluded its underwritten public offering, further bolstering its efforts to develop...